GlaxoSmithKline | GSK - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 688M 58M 2026-09
Alcon AG USD 53M 1000K 2026-06
Amgen USD 653M 94.99B 2026-09
argenx SE USD 1000K 0 2026-09
AstraZeneca USD 371M 31M 2026-09
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 403M 4M 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Fresenius EUR 81M 5M 2025-09
Fresenius Medical Care EUR 97.5M 14.5M 2026-09
Genmab DKK 139M 129M 2026-06
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
Glaxosmithkline GBP 264.74M 72.01M 2026-09
GRIFOLS EUR 141.43M 61.28M 2025-06
Hikma Pharmaceutical USD 67M 47M 2025-12
Lakefront Biotherapeutics EUR 1.72M 940K 2025-09
Lonza CHF 84M 14M 2025-06
Merck EUR 137M 33M 2026-06
Merck USD 525M 46M 2026-06
Novartis USD 468M 6M 2026-09
Novo Nordisk DKK 1.5B 28M 2026-06
Orion EUR 300K 400K 2026-09
Pfizer USD 662M 5M 2026-09
Philips EUR 84M 1000K 2026-09
Recordati EUR 22.13M 1.43M 2025-12
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 222M 65M 2026-09
Smith & Nephew USD 69M 1000K 2025-12
UCB EUR 49M 29M 2025-12